These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20180789)

  • 1. The effect of time-of-day dosing on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR: evidence for dosing flexibility with a Dual Delayed Release proton pump inhibitor.
    Lee RD; Mulford D; Wu J; Atkinson SN
    Aliment Pharmacol Ther; 2010 May; 31(9):1001-11. PubMed ID: 20180789
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor--evidence for dosing flexibility.
    Lee RD; Vakily M; Mulford D; Wu J; Atkinson SN
    Aliment Pharmacol Ther; 2009 Apr; 29(8):824-33. PubMed ID: 19243357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy.
    Metz DC; Vakily M; Dixit T; Mulford D
    Aliment Pharmacol Ther; 2009 May; 29(9):928-37. PubMed ID: 19298580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of electrocardiographic effect of dexlansoprazole MR, a novel modified-release formulation of the proton pump inhibitor dexlansoprazole, in healthy participants.
    Vakily M; Wu J; Atkinson SN
    J Clin Pharmacol; 2009 Dec; 49(12):1447-55. PubMed ID: 19826060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed release formulation: global clinical trial experience.
    Peura DA; Metz DC; Dabholkar AH; Paris MM; Yu P; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(10):1010-21. PubMed ID: 19735233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects.
    Zhang W; Wu J; Atkinson SN
    J Clin Pharmacol; 2009 Apr; 49(4):444-54. PubMed ID: 19318694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation--results from two randomized controlled studies.
    Sharma P; Shaheen NJ; Perez MC; Pilmer BL; Lee M; Atkinson SN; Peura D
    Aliment Pharmacol Ther; 2009 Apr; 29(7):731-41. PubMed ID: 19183157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dexlansoprazole MR for the management of gastroesophageal reflux disease.
    Behm BW; Peura DA
    Expert Rev Gastroenterol Hepatol; 2011 Aug; 5(4):439-45. PubMed ID: 21780890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
    Metz DC; Howden CW; Perez MC; Larsen L; O'Neil J; Atkinson SN
    Aliment Pharmacol Ther; 2009 Apr; 29(7):742-54. PubMed ID: 19210298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies.
    Vakily M; Lee RD; Wu J; Gunawardhana L; Mulford D
    Clin Drug Investig; 2009; 29(1):35-50. PubMed ID: 19067473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials.
    Vakily M; Zhang W; Wu J; Atkinson SN; Mulford D
    Curr Med Res Opin; 2009 Mar; 25(3):627-38. PubMed ID: 19232037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dexlansoprazole MR.
    Aslam N; Wright R
    Expert Opin Pharmacother; 2009 Oct; 10(14):2329-36. PubMed ID: 19708852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.
    Dabholkar AH; Han C; Paris MM; Perez MC; Atkinson SN; Peura DA
    Aliment Pharmacol Ther; 2011 Feb; 33(3):366-77. PubMed ID: 21118280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of dexlansoprazole MR in adolescents with symptomatic GERD.
    Kukulka M; Wu J; Perez MC
    J Pediatr Gastroenterol Nutr; 2012 Jan; 54(1):41-7. PubMed ID: 21716130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
    Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
    Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
    Abel C; Desilets AR; Willett K
    Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis - maintenance of healing and symptom relief.
    Howden CW; Larsen LM; Perez MC; Palmer R; Atkinson SN
    Aliment Pharmacol Ther; 2009 Nov; 30(9):895-907. PubMed ID: 19681809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover study.
    Miki M; Adachi K; Azumi T; Koshino K; Furuta K; Kinoshita Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1445-51. PubMed ID: 17032285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.